bian zhe tui jian

..............page:2086

WINDOW OF NEW DRUGS

..............page:2089-2090

International Pharmacovigilance Flash
ben kan ;

..............page:2091-2092

Lomitapide mesylate,a novel drug for familial hypercholesterolemia
ZHANG Xu-yang;LIU Bing-ni;LIU Deng-ke;WANG Ping-bao;Graduate School;Tianjin Medical University;Tianjin Institute of Pharmaceutical Research;

..............page:2093-2095+2100

Introduction of biosimilarity product policy in USA
LI Wei;BAI Yu;National Instituts for Food and Drug Contral;National Center for Drug Safety Evaluation;Center for Drug Evaluation;China Food and Drug Administration;

..............page:2096-2100

The strategy of U.S. patent protection about lipid-lowering drug atorvastatin
MAO Jin-long;LIN Cui-xia;SUN Rong;School of Pharmaceutical Sciences;Shandong University of Traditional Chinese Medicine;Division of Pharmacology;Shandong Academy of Chinese Medicine;School of Nursing;Shandong University of Traditional Chinese Medicine;

..............page:2101-2105

Structural alerts of genotoxic impurities
MA Lei;MA Yu-nan;CHEN Zhen;JIANG Yu;Center for Drug Evaluation;China Food and Drug Administration;

..............page:2106-2111

Requirements and common issues of genotoxicity study for pharmaceuticals
HUANG Fang-hua;WANG Qing-li;Center for Drug Evaluation;China Food and Drug Administration;

..............page:2112-2116

Establishment of a histopathology evaluation method of in vivo neurovirulence test in monkeys
QU Zhe;YANG Yan-wei;L Jian-jun;LIN Zhi;HUO Gui-tao;ZHANG Di;ZHANG Shuo;LI Shan-shan;WANG Ju-feng;LI Bo;National Center for Safety Evaluation of Drugs;National Institutes for Food and Drug Control;

..............page:2117-2122

Advances in absorbable hemostatic materials and their safety evaluation
ZHOU Wei;ZHANG Li;GUO Jia-bin;ZHAO Jun;PENG Shuang-qing;Disease Control and Prevention of Military Medical Science Academy of the;PLA Toxicological Evaluation Center;

..............page:2123-2126

Studies on the related substance of near period recombinant human growth hormone in two different forms
LI Jing;CHENG Su-yuan;ZHANG Hui;LIANG Cheng-gang;National Institutes for Food and Drug Control;

..............page:2127-2131+2143

Evolution of medicines and healthcare products regulatory agency
YAO Li-xin;Center for Pharmaceutical Information and Engineering Research;Peking University;

..............page:2132-2143

Establishment and validation of an ELISA method for quantitation of 13 serotype-specific anti-pneumococcal IgG antibodies in mouse serum
LIU Jia;WANG Xin-ru;ZHAO Zhi-qiang;LIU Fang-lei;HU Hao;YU Xu-bo;MAO Rui;LUO Shu-quan;XIE Gui-lin;Lanzhou Institute of Biological Products Co.;Ltd.;China National Biotech Group Company Limited;

..............page:2144-2149+2160

The research status and prospect of cancer chemoprevention by Chinese medical materials
ZOU Jian-ming;ZHANG Ying;Lintong Sanatorium in Lanzhou Military Area of Chinese PLA;Oncology Department of Guang’anmen Hospital of China Academy of Chinese Medical Sciences;

..............page:2150-2154

Advances in animal models of Parkinson’s disease
SUN Tao;Center for Drug Evaluation;China Food and Drug Administration;

..............page:2155-2160

Advances in drug therapy for wet age-related macular degeneration
SHI Wei-feng;GUI Cheng;LI Xiao-yu;LIU Gao-lin;Department of Clinical Pharmacy;Shanghai First People’s Hospital;School of Medicine;Shanghai Jiaotong University;

..............page:2161-2164

Silent genes provide new ideas for microbial pharmaceutical research
SHENG Nan;GU Jue-fen;Institute of Life Science and Technology;China Pharmaceutical University;

..............page:2165-2168+2184

Development of 11β-HSD1 inhibitors for metabolic syndrome
XIANG Qing;XU Wen;HUANG Ming-qing;LIN Yuan;Centre of Biomedical Research&Development;Fujian University of Traditional Chinese Medicine;Department of Pharmacy;Fujian University of Traditional Chinese Medicine;

..............page:2169-2173

Cost-effectiveness of insulin aspart and human soluble insulin for treatment of type 2 diabetes
XU Zhang-rong;JI Qiu-he;XU Fei;YE Qing;Diabetes Center&Endocrinology Department;306th Hospital of PLA;Department of Endocrinology and Metabolism;Xijing Hospital;Fourth Military Medical University;School of International Pharmaceutical Business;China Pharmaceutical University;Erasmus University;Institute of Health Policy & Management Rotterdam 3062 PA;Netherlands;

..............page:2174-2179

The influence of CYP2C19 gene polymorphism on efficacy of combinational antiplatelet therapy for cerebral small vessel disease
LIANG Xue-mei;TIAN Ming-xiu;The Third Ward of Neurology;Tianjing Forth Center Hospital;

..............page:2180-2184

Effects of β-asarone on neuroplasticity-related factors in hippocampus of rat model of depression
RONG Hua;DONG Hai-ying;GAO Zhi-ying;ZHANG Jing-yan;ZHANG Xiao-jie;Heilongjiang University of Chinese Medicine;

..............page:2185-2188+2194

Synthesis,activity testing and mechanism exploration of 3-hydroxy-3(5-chloro-2-hydroxyphenyl) propionyl-hydroxamic acids as Helicobacter pylori urease inhibitor
DENG Rui-cheng;WEI Wei;WANG Xu-dong;XIAO Zhu-ping;College of Chemistry and Chemical Engineering;Jishou University;

..............page:2189-2194

Synthesis and antidiabetic activities of novel pyrrolotriazine compounds as DPP-4 inhibitors
LI Cui-juan;LE Zhi-ping;ZHAO Chuan-sheng;Department of Chemistry;Nanchang University;Department of Medicinal Chemistry;Shanghai Sun-Sail Pharmaceutical Science & Technology Co.;Ltd.;

..............page:2195-2202

2014 nian zhong guo yao wu zhi ji da hui zai chang sha cheng gong ju ban

..............page:2202

Study on thin-layer chromatography identification and content determination of Duchesneae Indicae Herba
LI Ling-ling;HUANG Yan;BI Zhi-ming;State Key Laboratory of Natural Medicines;China Pharmaceutical University;

..............page:2203-2206

Analysis of China’s drug safety information in the last decade
ZHANG Hao;WU Zhi-ang;College of Business Administration;Shenyang Pharmaceutical University;

..............page:2207-2212